A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. (Record no. 25520731)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02288 a2200649 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517065805.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201801s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1557-3265 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1078-0432.CCR-15-1681 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Adjei, Alex A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180108 |
| 245 00 - TITLE STATEMENT | |
| Title | A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Date of publication, distribution, etc. | 05 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 2368-76 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Administration, Oral |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Combined Modality Therapy |
| General subdivision | methods |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Diphenylamine |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Half-Life |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maximum Tolerated Dose |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasms |
| General subdivision | blood |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Niacinamide |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylurea Compounds |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Protein Kinase Inhibitors |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sorafenib |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sulfonamides |
| General subdivision | adverse effects |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Richards, Donald A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | El-Khoueiry, Anthony |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Braiteh, Fadi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Becerra, Carlos H R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stephenson, Joe J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hezel, Aram F |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sherman, Morris |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Garbo, Lawrence |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leffingwell, Diane P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Iverson, Cory |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Miner, Jeffrey N |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shen, Zancong |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yeh, Li-Tain |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gunawan, Sonny |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wilson, David M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Manhard, Kimberly J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rajagopalan, Prabhu |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Krissel, Heiko |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Clendeninn, Neil J |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Related parts | vol. 22 |
| -- | no. 10 |
| -- | p. 2368-76 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1078-0432.CCR-15-1681">https://doi.org/10.1158/1078-0432.CCR-15-1681</a> |
| Public note | Available from publisher's website |
No items available.